Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
'We are pleased to have regained compliance with Nasdaq's minimum bid price requirement,' said Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals. 'This reflects our continued focus on bringing critical care products to patients and creating long-term value for our shareholders.'
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns 92% of Citius Oncology. For more information, please visit www.citiuspharma.com.
Forward-Looking Statements
This press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma or Citius Oncology. You can identify these statements by the fact that they use words such as 'will,' 'anticipate,' 'estimate,' 'expect,' 'plan,' 'should,' and 'may' and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma and Citius Oncology, are: our ability to maintain compliance with Nasdaq's continued listing standards; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; our ability to use the latest technology to support our commercialization efforts; our need for substantial additional funds; our ability to successfully implement and maintain distribution agreements with current or other future distribution partners; potential disruptions or performance issues involving third-party logistics providers; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission ('SEC') filings which are available on the SEC's website at www.sec.gov.
Investor Contact:Ilanit AllenVP, Corporate Communications & Investor RelationsCitius Pharmaceuticals, Inc.ir@citiuspharma.com908-967-6677 ext. 113
Media Contact:Greg SalsburgSTiR-communicationsGreg@STiR-communications.com908-967-6677 ext. 113
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
3 hours ago
- The Star
ReserveOne, backed by crypto heavyweights, set to raise over $1 billion in Nasdaq listing
FILE PHOTO: People walk outside the Nasdaq Marketsite in New York City, U.S., April 3, 2025. REUTERS/Brendan McDermid/File Photo (Reuters) -ReserveOne, a new crypto venture with ties to industry veterans and a former U.S. commerce secretary, will list on the Nasdaq through a merger with blank-check firm M3-Brigade Acquisition V Corp and is expected to raise more than $1 billion. The company will manage a portfolio of cryptocurrencies including bitcoin, ethereum and Solana, while aligning its holdings with the U.S. strategic crypto reserve, it said on Tuesday. The deal, expected to close in the October-December quarter, is the latest in a series of efforts to wrap crypto assets into equity and make them more appealing for traditional investors. The exponential stock price growth of Michael Saylor's Strategy, which pivoted to a bitcoin-focused business model in 2020, has also popularized the playbook. While ReserveOne is joining a crowded space, its CEO Jaime Leverton said the company's investment strategy and leadership give it an edge. Leverton previously led crypto miner and computing provider Hut 8. "Our management team and anticipated board of directors bring a really unique pedigree and diversity of background between Wall Street and regulatory and crypto," Leverton told Reuters. Sebastian Bea, a former executive at asset managers BlackRock and Coinbase Asset Management , will serve as ReserveOne's president and head of investment. Its board will be chaired by stablecoin giant Tether's co-founder Reeve Collins and will include former Blackstone dealmaker Chinh Chu and Wilbur Ross, the Secretary of Commerce in the first Trump administration. "Wilbur was a skeptic. But over the last number of months, he's really opened up to this space," Leverton said. The company also plans to generate returns by offering some assets for lending and institutional staking — a practice where crypto is locked up in exchange for periodic payouts. and Kraken are among the investors in the blank-check deal, contributing up to $750 million through a combination of equity and convertible debt offering. Blank-check firms such as M3-Brigade are shell entities that raise capital through an IPO with the sole purpose of merging with a private company, which then becomes publicly traded. (Reporting by Niket Nishant in Bengaluru; Editing by Sahal Muhammed)
Malaysian Reserve
4 hours ago
- Malaysian Reserve
BTQ Technologies Corp. Announces Brokered LIFE Financing of C$40 Million
/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, BC and SEOUL, Korea, July 8, 2025 /CNW/ – BTQ Technologies Corp. (the 'Company') (CBOE CA: BTQ) (FSE: NG3) (OTCQX: BTQQF), a global quantum technology company focused on securing mission-critical networks is pleased to announce a best efforts private placement, of 5,555,555 common shares of the Company ('Common Shares') at a price of C$7.20 per Common Share, for aggregate gross proceeds of C$40,000,000 (the 'Offering'). A.G.P. Canada Investments ULC ('Agent') is acting as the sole bookrunner and agent for the Offering and A.G.P./Alliance Global Partners is acting as sole U.S. placement agent for the Offering. The Company plans to use the net proceeds for general corporate purposes, working capital and to accelerate the development of both hardware and software products and potential acquisitions. The Offering is scheduled to close on or about July 10, 2025 ('Closing Date'), and is subject to certain conditions customary for transactions of this nature, including, but not limited to, the receipt of all necessary approvals, including of Cboe Canada Inc. The Company has agreed to pay the Agent a cash fee equal to 7% of the gross proceeds from the Offering. In addition, upon closing of the Offering, the Company has agreed to issue the Agent non-transferable broker warrants (each, a 'Broker Warrant') equal to 2.5% of the total number of Common Shares sold pursuant to the Offering. Each Broker Warrant will be exercisable for one Common Share at a price of C$12.60 per Broker Warrant and is exercisable for a period of 60 months following the completion of the Offering. The Common Shares to be issued under the Offering will be offered to purchasers pursuant to the listed issuer financing exemption ('LIFE Exemption') under Part 5A of National Instrument 45-106 – Prospectus Exemptions ('NI 45-106'), in the provinces of British Columbia, Alberta and Ontario. The Common Shares offered under the LIFE Exemption will not be subject to resale restrictions pursuant to applicable Canadian securities laws. The Common Shares may also be offered to persons in the United States or to, or for the account or benefit of, 'U.S. persons' (as defined in Regulation S under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act')) pursuant to exemptions from the registration requirements under the and all applicable U.S. state securities laws, as well as outside Canada and the United States on a basis which does not require the qualification or registration of any of the Company's securities or require the Company to be subject to any ongoing disclosure requirements under any domestic securities laws. There is an offering document related to the LIFE Exemption portion of the Offering that can be accessed under the Company's profile on SEDAR+ at and on the Company's website at Prospective investors should read this offering document before making an investment decision. The securities to be offered pursuant to the Offering have not been, and will not be, registered under the U.S. Securities Act or under any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, a 'U.S. person' absent registration or any applicable exemption from the registration requirements under the U.S. Securities Act and applicable U.S. state securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About BTQ BTQ Technologies Corp. (Cboe CA: BTQ | FSE: NG3 | OTCQX: BTQQF) is a vertically integrated quantum company accelerating the transition from classical networks to the quantum internet. Backed by a broad patent portfolio, BTQ pioneered the industry's first commercially significant quantum advantage and now delivers a full-stack, neutral-atom quantum computing platform with end-to-end hardware, middleware, and post-quantum security solutions for finance, telecommunications, logistics, life sciences, and defense. Forward-Looking Statements: Certain statements herein contain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Such forward-looking statements or information include but are not limited to statements or information with respect to the timing of the closing of the Offering, the use of proceeds from the Offering, business plans of the Company, including with respect to its research partnerships, and anticipated markets in which the Company may be listing its common shares and its use of proceeds from the Offering. Forward-looking statements or information often can be identified by the use of words such as 'anticipate', 'intend', 'expect', 'plan' or 'may' and the variations of these words are intended to identify forward-looking statements and information. The Company has made numerous assumptions including among other things, assumptions about general business and economic conditions, the development of post-quantum algorithms and quantum vulnerabilities, and the quantum computing industry generally. The foregoing list of assumptions is not exhaustive. Although management of the Company believes that the assumptions made and the expectations represented by such statements or information are reasonable, there can be no assurance that forward-looking statements or information herein will prove to be accurate. Forward-looking statements and information are based on assumptions and involve known and unknown risks which may cause actual results to be materially different from any future results, expressed or implied, by such forward-looking statements or information. These factors include risks relating to: the availability of financing for the Company; business and economic conditions in the post-quantum and encryption computing industries generally; the speculative nature of the Company's research and development programs; the supply and demand for labour and technological post-quantum and encryption technology; unanticipated events related to regulatory and licensing matters and environmental matters; changes in general economic conditions or conditions in the financial markets; changes in laws (including regulations respecting blockchains); risks related to the general economic conditions, the ability to obtain financing as required, and causing potential delays to research and development activities; and other risk factors as detailed from time to time. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws. The CBOE Canada does not accept responsibility for the adequacy or accuracy of the content of this Press Release.
Malaysian Reserve
11 hours ago
- Malaysian Reserve
THESIS GOLD CLOSES C$27.5 MILLION UPSIZED BOUGHT DEAL PRIVATE PLACEMENT
/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, BC, July 8, 2025 /CNW/ – Thesis Gold Inc. ('Thesis' or the 'Company') (TSXV: TAU) (WKN: A3EP87) is pleased to announce that it has completed its previously announced underwritten offering, including the full exercise of the over-allotment option, for gross proceeds of approximately C$27.5 million (the 'Offering'). The Offering consisted of (i) 5,770,000 common shares of the Company issued as 'flow-through shares' with respect to 'Canadian exploration expenses' (each within the meaning of the Income Tax Act (Canada)) (the 'BC CEE Flow-Through Shares') at a price of C$1.56 per BC CEE Flow-Through Share for aggregate gross proceeds of C$9,001,200; (ii) 11,114,000 common shares of the Company issued as 'flow-through shares' with respect to 'Canadian exploration expenses' (each within the meaning of the Tax Act) ('National CEE Flow-Through Shares') at a price of C$1.445 per National CEE Flow-Through Share for aggregate gross proceeds of C$16,059,730 and (iii) 1,930,000 common shares of the Company issued as 'flow-through shares' with respect to 'Canadian exploration expenses' (each within the meaning of the Tax Act) ('Traditional Flow-Through Shares') at a price of C$1.30 per Traditional Flow-Through Share for aggregate gross proceeds of C$2,509,000 (the BC CEE Flow-Through Shares, the National CEE Flow- Through Shares and the Traditional Flow-Through Shares are, collectively referred to as the 'Flow-Through Shares'). Existing shareholder Centerra Gold Inc. ('Centerra') participated in the Offering to maintain its shareholder interest in the Company. The gross proceeds of the Offering will be used by the Company to incur eligible 'Canadian exploration expenses' that qualify as 'flow-through mining expenditures' as such terms are defined in the Income Tax Act (Canada) (the 'Qualifying Expenditures') related to the Lawyers Ranch project in British Columbia. Qualifying Expenditures with respect to the BC CEE Flow-Through Shares with also qualify as 'BC flow-through mining expenditures' as such term is defined in the Income Tax Act (British Columbia). All Qualifying Expenditures will be renounced in favour of the subscribers for the Flow-Through Shares effective on or before December 31, 2025. Scotiabank acted as sole bookrunner, together with Clarus Securities Inc. as co-lead underwriter, on behalf of a syndicate of underwriters which also included Haywood Securities Inc., Jett Capital Advisors, LLC, National Bank Financial Inc. and Cormark Securities Inc. (collectively, the 'Underwriters'). The Underwriters received a cash commission equal to 6.0% of the gross proceeds from the Offering, paid from the Company's existing cash reserves. All securities issued pursuant to the Offering are subject to a four-month hold period expiring on November 9, 2025, in accordance with the policies of the TSX Venture Exchange ('TSXV') and applicable securities laws. The Offering is subject to final approval by the TSXV. The securities issued under the Offering have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the U.S. Securities Act'), or any U.S. state securities laws, and may not be offered, sold or resold in the 'United States' (as such term is defined in Regulation S under the U.S. Securities Act) with registration under the U. S. Securities Act and all applicable U.S. state securities laws, or in compliance with an exemption therefrom. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. About Thesis Gold Inc. Thesis Gold Inc. is a resource development company focused on unlocking the potential of its 100% owned Lawyers-Ranch Project, located in British Columbia's prolific Toodoggone Mining District. The recently completed Preliminary Economic Assessment (PEA) highlights robust project economics, including a 35.2% after-tax IRR and an after-tax NPV5% of C$1.28 billion, demonstrating the potential for significant value creation. The Company's 2025 roadmap includes a robust exploration and drill program, delivery of a Pre-Feasibility Study on the combined Lawyers-Ranch Project, and commencement of the Environmental Impact Assessment Process. Through these strategic moves, Thesis Gold intends to elevate the Lawyers-Ranch Project to the forefront of global precious metals ventures. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Cautionary Statement Regarding Forward-Looking Information This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the use of proceeds in respect of the Offering, final approval of the TSXV, and the future plans or prospects of the Company. Generally, forward-looking information can be identified by the use of forward-looking terminology such as 'plans', 'expects' or 'does not expect', 'is expected', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates' or 'does not anticipate', or 'believes', or variations of such words and phrases or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved'. Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable by management, are inherently subject to business, market, and economic risks, uncertainties, and contingencies that may cause actual results, performance, or achievements to be materially different from those expressed or implied by forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Other factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis, which is available on the Company's profile on SEDAR+ at The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
